Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.

Delamanid (DLM) and pretomanid (PTM) are recent additions to the anti-tuberculosis (TB) drug armamentarium, and they offer more effective options for drug-resistant TB treatment. In particular, DLM is included in Group C, which is recommended for use in longer multidrug-resistant (MDR)-TB regimens. Previous studies have shown that resistance to DLM/PTM is caused by mutations in the ddn , fgd1 , fbiA , fbiB , fbiC , and fbiD genes, which are related to the F 420 -dependent bioactivation pathway. Herein, we conduct in vitro selection of DLM-resistant strains using clinical Mycobacterium tuberculosis (MTB) isolates with various drug resistance profiles. The spontaneous resistance frequency of drug-susceptible (DS) MTB (1.14 × 10 -6 to 1.04 × 10 -4 ) to DLM was similar to that of H37Rv (8.88 × 10 -6 to 9.96 × 10 -6 ) but higher than those of multidrug-resistant MTB (2.03 × 10 -7 to 3.18 × 10 -6 ) and extensively drug-resistant (XDR) MTB (4.67 × 10 -8 to 3.60 × 10 -6 ). Of the 100 independently selected DLM-resistant MTB mutants, 65% harbored mutations in genes associated with either DLM prodrug activation ( ddn , 39.73%; fgd1 , 16.44%) or the F 420 biosynthetic pathway ( fbiA , 16.44%; fbiB , 5.48%; fbiC , 21.92%). Of the 45 mutations we identified, 38 were not previously reported. A structure analysis revealed that several point mutations affected the ligand binding or structural stability of enzymes related to DLM resistance, which would block the enzyme activity required for prodrug activation. Our results elucidate the in vitro spontaneous DLM-resistance patterns of different clinical strains, which could improve the understanding of the causes of DLM resistance in clinical strains and of the effects on drug resistance of different mutations in genes that are related to the DLM activation pathway.